[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organ-dysfunction-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organ-dysfunction-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100487180","erector-spinae-plane-block-improves-organ-dysfunction-in-septic-patients-with-acute-gastrointestinal-injury-100487180",false,"NCT05623722","Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury","Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Septic patients with acute gastrointestinal injury grade II or III;\n* Age over 18 years;\n* Expected to stay in the ICU for at least 3 days or longer;\n\nExclusion Criteria:\n\n* Mean arterial pressure less than 65 mmHg after fluid resuscitation, or requirement for an intravenous norepinephrine dose of greater than 0.5 µg\u002Fkg\u002Fmin to maintain a normal mean arterial pressure;\n* Heart rates less than 50 beats\u002Fmin, or concomitant with moderate-to-severe atrioventricular block without a pacemaker;\n* Contraindications for erector spinae plane blocks, including infection of the puncture site, spinal diseases or immobilization;\n* Primary gastrointestinal disorders requiring a surgical procedure, such as mechanical intestinal obstruction, massive gastrointestinal hemorrhage, and gastrointestinal perforation;\n* Gastrointestinal operation within one week before enrollment;\n* Neuromuscular disorders;\n* Coagulation abnormalities：activated prothrombin time or prothrombin time is prolonged with 2 folds, or platelet count less than 50×109\u002FL;\n* End-stage malignant tumor or cachexia;\n* History of allergy to amide anesthetics;\n* Known pregnancy;","ALL","18 Years",{"count":19,"type":20},116,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a prospective, multicenter, parallel-group, open-label, randomized controlled clinical trial. Sepsis is defined as organ dysfunction induced by infections. And sepsis and gastrointestinal injury can be the leading cause for each other. Our previous study showed erector spinae plane block improved the organ dysfunctions in patients with AGI. The aim of the clinical trial is to investigate erector pinae plane block improves the organ dysfunction in septic patients with acute gastrointestinal injury.",[26,27,28],"Sepsis","Acute Gastrointestinal Injury","Organ Dysfunction Syndrome",[26,27,28,30],"Erector spinae plane block","RECRUITING","2025-08-31",{"date":34,"type":35},"2025-09-08","ACTUAL",{"date":37,"type":35},"2022-12-29",{"date":39,"type":20},"2026-12-31",{"name":41,"class":42},"Jing Cai, MD","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100552496","efficacy-of-sglt2-inhibitors-in-adults-with-sepsis-100552496","NCT06473844","Efficacy of SGLT2 Inhibitors in Adults With Sepsis","Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Sepsis: A Feasibility Study for a Multicenter Double-Blind Randomized Placebo-Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or above\n* New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)\n* Provision of signed and dated informed consent form from participant or surrogate\n* Ability to take and adhere to oral and enteral medication regimen\n* Willingness to comply\n\nExclusion Criteria:\n\n* Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)\n* Impaired renal function\n* Clinically unstable or in refractory hypotension\n* History of ketoacidosis\n* Gastrointestinal surgery or GI absorption \u002F malabsorption disorder\n* Pregnancy\n* Known allergic or hypersensitivity reactions to any SGLT2 inhibitors\n* Treatment with another investigational drug or other interventions within 30 days prior to trial",{"count":52,"type":20},60,[23],"Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:\n\n(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.\n\n(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.",[26,56,57,58,28],"Inflammation","SGLT2 Inhibitors","Critically Ill",[60,26,61,58,62],"SGLT2 inhibitors","Inflammatory Markers","Organ dysfunction","2025-03-17",{"date":65,"type":35},"2025-03-19",{"date":67,"type":35},"2025-03-05",{"date":69,"type":20},"2027-02-28",{"name":71,"class":72},"Hospital Authority, Hong Kong","OTHER_GOV",3]